Ironwood Pharmaceuticals (NASDAQ:IRWD) Upgraded at BidaskClub

BidaskClub upgraded shares of Ironwood Pharmaceuticals (NASDAQ:IRWD) from a hold rating to a buy rating in a research report sent to investors on Friday, BidAskClub reports.

Several other equities analysts have also issued reports on IRWD. Cowen set a $12.00 price target on Ironwood Pharmaceuticals and gave the stock a hold rating in a research report on Friday, September 13th. ValuEngine downgraded Ironwood Pharmaceuticals from a buy rating to a hold rating in a research report on Friday, November 1st. Eight investment analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. The stock currently has an average rating of Hold and a consensus target price of $14.50.

Ironwood Pharmaceuticals stock opened at $12.48 on Friday. The firm has a fifty day simple moving average of $10.86 and a two-hundred day simple moving average of $10.19. Ironwood Pharmaceuticals has a twelve month low of $7.91 and a twelve month high of $15.21. The company has a market capitalization of $1.96 billion, a PE ratio of -13.14 and a beta of 1.87.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last released its quarterly earnings data on Thursday, October 31st. The biotechnology company reported $0.40 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.10 by $0.30. Ironwood Pharmaceuticals had a negative return on equity of 15.83% and a negative net margin of 9.67%. The firm had revenue of $131.17 million for the quarter, compared to the consensus estimate of $97.10 million. During the same quarter in the previous year, the business earned ($0.27) earnings per share. The company’s quarterly revenue was up 99.7% on a year-over-year basis. As a group, analysts predict that Ironwood Pharmaceuticals will post 0.49 earnings per share for the current year.

Several institutional investors have recently bought and sold shares of IRWD. Amundi Pioneer Asset Management Inc. purchased a new position in Ironwood Pharmaceuticals during the 1st quarter valued at $63,000. Diamond Hill Capital Management Inc. bought a new position in Ironwood Pharmaceuticals in the second quarter worth about $115,000. Signition LP bought a new position in Ironwood Pharmaceuticals in the third quarter worth about $100,000. Russell Investments Group Ltd. purchased a new stake in Ironwood Pharmaceuticals in the second quarter worth about $135,000. Finally, Prudential Financial Inc. lifted its holdings in Ironwood Pharmaceuticals by 9.6% in the second quarter. Prudential Financial Inc. now owns 14,124 shares of the biotechnology company’s stock worth $155,000 after buying an additional 1,240 shares during the period.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc, a commercial biotechnology company, engages in the research, development, and commercialization of human therapeutic products. The company markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and CONSTELLA name in the European Union; MD-7246, an oral, intestinal, non-opioid, pain-relieving agent for patients suffering from IBS with diarrhea; and IW 3718, a gastric retentive formulation of a bile acid sequestrant, which is in Phase III clinical trials for the treatment of GERD.

Recommended Story: Accumulation/Distribution

Analyst Recommendations for Ironwood Pharmaceuticals (NASDAQ:IRWD)

Receive News & Ratings for Ironwood Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.